Syros Pharmaceuticals reports Q2 EPS ($1.30), consensus ($1.13)

Reports Q2 revenue $2.83M, consensus $3.50M. “In the second quarter and recent months, we continued to focus on clinical execution, enrolling patients in our SELECT-AML-1 and SELECT-MDS-1 trials and advancing both studies toward data readouts in the fourth quarter of 2023 and third quarter of 2024, respectively,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We look forward to sharing initial data from our SELECT-AML-1 trial in the fourth quarter, which will provide the first direct comparison of patients with RARA overexpression treated with the triplet regimen of tamibarotene, venetoclax and azacitidine compared to those treated with venetoclax and azacitidine alone.” Simonian continued, “In parallel, we progressed our ongoing efforts with SY-2101. We are gathering pharmacokinetic data from our ongoing dose confirmation study and remain on track to provide an update on the next steps for a registration-enabling study in APL in the second half of 2023. In addition, we presented encouraging data for SY-5609 at the ASCO Annual Meeting in June. These data, which generated substantial enthusiasm from clinicians and key opinion leaders, further reinforce the potential of selective CDK7 inhibition and support our ongoing exploration of out-licensing opportunities to maximize the potential of this program.”